Infections after lung transplantation

被引:32
作者
Avery, Robin K. [1 ]
机构
[1] Cleveland Clin Fdn, Dept Infect Dis, Cleveland, OH 44195 USA
关键词
infections; lung transplant; prophylaxis;
D O I
10.1055/s-2006-954612
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Despite advances in prophylaxis and therapy, infections remain a major source of morbidity and mortality after lung transplantation. Lung transplant recipients are at increased risk for both community-acquired and nosocomial pathogens, which may develop at various time points. The risk of infections increases with the intensity of immunosuppression. Careful assessment of the recipient is essential to assure adequate prophylactic or preemptive therapy. Aggressive prophylaxis for some infections (e.g., cytomegalovirus) has substantially reduced the prevalence of serious infections due to this organism. Tuberculin-positive individuals should be treated with prophylactic isoniazid to reduce the chance for reactivation of tuberculosis following transplantation. Myriad opportunistic pathogens (including various viruses, bacteria, fungi, etc.) may complicate transplantation, owing to the effects of multiagent immunosuppressive therapy. This review addresses the salient pathogens that may infect organ transplant recipients, and discusses strategies to prevent or treat specific pathogens in this highly susceptible patient population.
引用
收藏
页码:544 / 551
页数:8
相关论文
共 83 条
[61]  
Palmer SM, 1998, J HEART LUNG TRANSPL, V17, P1029
[62]   Safety of aerosolized amphotericin B lipid complex in lung transplant recipients [J].
Palmer, SM ;
Drew, RH ;
Whitehouse, JD ;
Tapson, VF ;
Davis, RD ;
McConnell, RR ;
Kanj, SS ;
Perfect, JR .
TRANSPLANTATION, 2001, 72 (03) :545-548
[63]   Posttransplant lymphoproliferative disorder - Incidence, presentation, and response to treatment in lung transplant recipients [J].
Reams, D ;
McAdams, HP ;
Howell, DN ;
Steele, MP ;
Davis, RD ;
Palmer, SM .
CHEST, 2003, 124 (04) :1242-1249
[64]   Azithromycin in, patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa -: A randomized controlled trial [J].
Saiman, L ;
Marshall, BC ;
Mayer-Hamblett, N ;
Burns, JL ;
Quittner, AL ;
Cibene, DA ;
Coquillette, S ;
Fieberg, AY ;
Accurso, FJ ;
Campbel, PW .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (13) :1749-1756
[65]  
Saiman Lisa, 2003, American Journal of Infection Control, V31, pS1
[66]   Pneumatosis intestinalis with Clostridium difficile colitis as a cause of acute abdomen after lung transplantation [J].
Schenk, P ;
Madl, C ;
Kramer, L ;
Ratheiser, K ;
Kranz, A ;
Zauner, C ;
Stain, C ;
Birsan, T ;
Klepetko, W ;
Müller, C .
DIGESTIVE DISEASES AND SCIENCES, 1998, 43 (11) :2455-2458
[67]   Risk factors for bronchiolitis obliterans: A systematic review of recent publications [J].
Sharples, LD ;
McNeil, K ;
Stewart, S ;
Wallwork, J .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2002, 21 (02) :271-281
[68]   Lamivudine prophylaxis for hepatitis B virus infection after lung transplantation [J].
Shitrit, ABG ;
Kramer, MR ;
Bakal, I ;
Morali, G ;
Ben Ari, Z ;
Shitrit, D .
ANNALS OF THORACIC SURGERY, 2006, 81 (05) :1851-1852
[69]  
Singh N, 2004, Transpl Infect Dis, V6, P58, DOI 10.1111/j.1399-3062.2004.062_2.x
[70]   Aspergillus infections after lung transplantation:: Clinical differences in type of transplant and implications for management [J].
Singh, N ;
Husain, S .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2003, 22 (03) :258-266